Develops reformulated medicines for rare diseases, including an injectable nimodipine treatment intended for hospitals caring for people with bleeding around the brain caused by a ruptured aneurysm.
10-K for FY2026, filed Jun 18, 2026We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes…View ↗
GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address…View ↗
About aneurysmal Subarachnoid Hemorrhage (aSAH) aSAH is bleeding over the surface of the brain in the subarachnoid space between the brain…View ↗
Hospitals and intensive-care units are potential buyers; hospital administrators and critical- and neuro-intensive-care physicians participate in purchasing decisions for their institutions or units.
10-K for FY2026, filed Jun 18, 2026
10-Q for Q2 FY2027, filed Nov 12, 2026
−$2.1MView ↗
Funding for other candidates
The latest report says it will not resume internal funding for its other drug candidates under its current plan, after the older report deferred their development while prioritizing its lead candidate.
10-K for FY2023, filed Jun 23, 2023 10-K for FY2026, filed Jun 18, 2026In April 2023, we announced the strategic decision to prioritize development of GTX-104 with a goal to advance to commercialization, while…View ↗
In May 2023, we implemented a strategic realignment plan that resulted in engaging a new management team, streamlining our research and…View ↗
Loading...